Clinical Trials Logo

Oropharynx Cancer clinical trials

View clinical trials related to Oropharynx Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05535023 Withdrawn - Clinical trials for Head and Neck Cancer

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Start date: August 24, 2022
Phase: Phase 2
Study type: Interventional

To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the disease

NCT ID: NCT04892875 Withdrawn - Clinical trials for Head and Neck Cancer

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

PANTHEoN
Start date: December 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of chemotherapy and radiation in combination with the investigational study drugs zimberelimab (AB122) and etrumadenant (AB928) in subjects with a locally advances head or neck cancer. The study will also ask how the study drugs change the following: - The microbiome that lives in the mouth and on the skin - Immune cells as they respond to a skin wound - Scarring (fibrosis) caused by radiation After completing a screening phase, subjects will be assigned to one of three cohorts: - Cohort 1: Subjects who will receive cisplatin, radiation and zimberelimab followed by zimberelimab only. - Cohort 2: Subjects who will receive cisplatin, radiation, zimberelimab and etrumadenant followed by zimberelimab and etrumadent. - Cohort 3: Subjects who will receive cisplatin and radiation followed by an observation period. All three cohorts will be followed for a 24 months following the conclusion of the chemoradiation.

NCT ID: NCT04001413 Withdrawn - Oropharynx Cancer Clinical Trials

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Start date: September 17, 2019
Phase: Phase 2
Study type: Interventional

Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker) after treatment with curative intent.